Drug discrimination under a concurrent fixed-interval fixed-interval schedule.
Pigeons were trained to discriminate 5.0 mg/kg pentobarbital from saline under a concurrent fixed-interval (FI) FI schedule of food presentation on which, after pentobarbital administration, responses on one key were reinforced with food under an FI 60-s component and responses on the other key were reinforced under an FI 240-s component. After saline administration, the schedule contingencies on the two keys were reversed. After both pentobarbital and saline, pigeons responded more frequently on the key on which responses had been programmed to produce the reinforcer under the FI 60 component of the concurrent schedule. The schedule was changed to concurrent FI 150 FI 150 s for drug-substitution tests. In each bird, increasing doses of pentobarbital, ethanol, and chlordiazepoxide produced increases in the proportion of responses on the key on which responses had been reinforced under the FI 60 component after pentobarbital administration during training sessions. The proportion of responses on that key was slightly lower for ethanol than for chlordiazepoxide and pentobarbital. At a dose of pentobarbital higher than the training dose, responding decreased on the key that had been reinforced under the FI 60 component during training sessions. Phencyclidine produced less responding on the key programmed under the FI 60-s component than did pentobarbital. Methamphetamine produced responding primarily on the key on which responses had been reinforced under the FI 60-s component after saline administration.
McMillan
D E
DE
Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock 72205, USA. mcmillandonalde@exchange.uams.edu
Li
M
M
Hardwick
W C
WC
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001070:Appetitive Behavior / Q000187:drug effects*; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D002707:Chlordiazepoxide / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000494:pharmacology*; D006213:Hallucinogens / Q000494:pharmacology; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008297:Male; D008694:Methamphetamine / Q000494:pharmacology; D009042:Motivation; D010424:Pentobarbital / Q000494:pharmacology*; D010622:Phencyclidine / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D012055:Reinforcement Schedule
D014151:Anti-Anxiety Agents; D002492:Central Nervous System Depressants; D000697:Central Nervous System Stimulants; D006213:Hallucinogens; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs; D000431:Ethanol; D008694:Methamphetamine; D002707:Chlordiazepoxide; D010424:Pentobarbital; D010622:Phencyclidine